The world's second largest influenza vaccine provider will construct a new world-class biotech manufacturing facility in Australia - a $1.8 billion dollar deal in total. Seqirus who will invest $800 million, aims to supply influenza vaccines to Australia and across the globe with the only cell-based influenza vaccine manufacturing facility in the Southern Hemisphere. They will also manufacture their proprietary MF59 which is a substance added to some vaccines to improve immune response and reduce the amount of antigen in vaccines. This means that more doses can be manufactured quicker. | https://www.seqirus.com/news/seqirus-will-build-world-class-vaccine-manufacturing-facility